Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer

Purpose: Myeloid cells are a prominent immunosuppressive component within the stroma of pancreatic ductal adenocarcinoma (PDAC). Previously, targeting myeloid cells has had limited success. Here, we sought to target the myeloid cells through modifying a specific stromal component. Experimental Design: A murine model of metastatic PDAC treated with an irradiated whole-cell PDAC vaccine and PDAC specimens from patients treated with the same type of vaccine were used to assess the immune-modulating effect of stromal hyaluronan (HA) degradation by PEGPH20. Results: Targeting stroma by degrading HA with PEGPH20 in combination with vaccine decreases CXCL12/CXCR4/CCR7 immunosuppressive signaling axis expression in cancer-associated fibroblasts, myeloid, and CD8+ T cells, respectively. This corresponds with increased CCR7− effector memory T-cell infiltration, an increase in tumor-specific IFNγ, and improved survival. In the stroma of human PDACs treated with the same vaccine, decreased stromal CXCR4 expression significantly correlated with decreased HA and increased cytotoxic activities, suggesting CXCR4 is an important therapeutic target. Conclusions: This study represents the first to dissect signaling cascades following PDAC stroma remodeling via HA depletion, suggesting this not only overcomes a physical barrier for immune cell trafficking, but alters myeloid function leading to downstream selective increases in effector memory T-cell infiltration and antitumor activity.

[1]  P. Philip,et al.  Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Paolo P. Provenzano,et al.  Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma. , 2018, Cancer research.

[3]  D. V. Von Hoff,et al.  Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression , 2018, Clinical Cancer Research.

[4]  S. Lowe,et al.  Tumor Cell‐Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy , 2018, Immunity.

[5]  Lei Zheng,et al.  HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Pierce,et al.  T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma , 2017, Cancer Immunology Research.

[7]  R. Korn,et al.  Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours , 2017, British Journal of Cancer.

[8]  M. Miyasaka,et al.  Regulation of CCR7-dependent cell migration through CCR7 homodimer formation , 2017, Scientific Reports.

[9]  Adam A. Margolin,et al.  Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. , 2017, Cell reports.

[10]  G. Miller,et al.  Myeloid-derived suppressor cells and their role in pancreatic cancer , 2016, Cancer Gene Therapy.

[11]  A. Biankin,et al.  CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma , 2016, Cancer cell.

[12]  David S. Wishart,et al.  Heatmapper: web-enabled heat mapping for all , 2016, Nucleic Acids Res..

[13]  D. Weaver,et al.  Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy , 2016, Nature Medicine.

[14]  J. Couchman,et al.  Extracellular matrix component signaling in cancer. , 2016, Advanced drug delivery reviews.

[15]  Umar Mahmood,et al.  Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. , 2015, Cancer cell.

[16]  C. Iacobuzio-Donahue,et al.  Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer , 2015, Science Signaling.

[17]  D. Pardoll Cancer and the Immune System: Basic Concepts and Targets for Intervention. , 2015, Seminars in oncology.

[18]  T. Ludwig,et al.  Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors , 2015, Cancer Immunology Research.

[19]  R. Jain,et al.  CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice , 2015, Hepatology.

[20]  E. Jaffee,et al.  Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Caroline H. Diep,et al.  Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer , 2015, Clinical Cancer Research.

[22]  E. Jaffee,et al.  PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors , 2015, Journal of immunotherapy.

[23]  H. Shepard,et al.  Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy , 2014, Molecular Cancer Therapeutics.

[24]  Lei Zheng,et al.  A preclinical murine model of hepatic metastases. , 2014, Journal of visualized experiments : JoVE.

[25]  E. Eichler,et al.  Evolutionary-new centromeres preferentially emerge within gene deserts , 2008, Genome Biology.

[26]  R. Hruban,et al.  Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation , 2014, Cancer Immunology Research.

[27]  Stephen A. Sastra,et al.  Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. , 2014, Cancer cell.

[28]  H. Shepard,et al.  Characterization of a Novel Recombinant Hyaluronan Binding Protein for Tissue Hyaluronan Detection , 2014, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[29]  R. Jain,et al.  Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal‐derived factor 1 alpha/C‐X‐C receptor type 4 axis and myeloid differentiation antigen–positive myeloid cell infiltration in mice , 2014, Hepatology.

[30]  A. Rucki,et al.  Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies. , 2014, World journal of gastroenterology.

[31]  Derek S. Chan,et al.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[32]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[33]  E. Jaffee,et al.  Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. , 2013, Gastroenterology.

[34]  J. Taube,et al.  Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. , 2013, Journal of visualized experiments : JoVE.

[35]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[36]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[37]  H. Shepard,et al.  Effective targeting of the tumor microenvironment for cancer therapy. , 2012, Anticancer research.

[38]  D. Gabrilovich,et al.  Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.

[39]  Carlos Cuevas,et al.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[40]  V. Kosma,et al.  Hyaluronan in human malignancies. , 2011, Experimental cell research.

[41]  R. Jain,et al.  CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies? , 2011, Clinical Cancer Research.

[42]  K. Lillemoe,et al.  A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation , 2011, Annals of surgery.

[43]  James O. Jones,et al.  Suppression of Antitumor Immunity by Stromal Cells Expressing , 2022 .

[44]  P. O'Connor,et al.  Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models , 2010, Molecular Cancer Therapeutics.

[45]  S. Rosenberg,et al.  Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma , 2010, Journal of immunotherapy.

[46]  Y. Iwakura,et al.  CXC Chemokine Ligand 12 Promotes CCR7-Dependent Naive T Cell Trafficking to Lymph Nodes and Peyer’s Patches , 2009, The Journal of Immunology.

[47]  I. C. Leão,et al.  Effective Depletion of Regulatory T Cells Allows the Recruitment of Mesothelin‐Specific CD8+ T Cells to the Antitumor Immune Response Against a Mesothelin‐Expressing Mouse Pancreatic Adenocarcinoma , 2008, Clinical and translational science.

[48]  E. Jaffee,et al.  Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation , 2008, Clinical Cancer Research.

[49]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[50]  F. Balkwill Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[51]  Antonio Lanzavecchia,et al.  Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.

[52]  T. Oshikiri,et al.  CD8+ Tumor-Infiltrating Lymphocytes Together with CD4+ Tumor-Infiltrating Lymphocytes and Dendritic Cells Improve the Prognosis of Patients with Pancreatic Adenocarcinoma , 2004, Pancreas.

[53]  E. Jaffee,et al.  Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. , 2001, Cancer research.

[54]  C. de Lange Davies,et al.  Hyaluronidase reduces the interstitial fluid pressure in solid tumours in a non-linear concentration-dependent manner. , 1998, Cancer letters.

[55]  M. Parmentier,et al.  Genomic organization and promoter characterization of human CXCR4 gene 1 , 1998, FEBS letters.

[56]  E. Jaffee,et al.  Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer. , 2017, Cancer research.

[57]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[58]  Rogers Hj The structure and function of hyaluronate. , 1961 .

[59]  H. Rogers The structure and function of hyaluronate. , 1961, Biochemical Society symposium.